Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 52-15 PALLAS 

PALLAS: PALbociclib CoLlaborative Adjuvant Study:
A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

DESIGN

please click on the picture to see a larger version

Study Chair
Michael Gnant, MD, Vienna

Lead Trial Coordinators
Holly Shaw

Trial Coordinators
Poonam Jani

Trial Monitors
Magdalena Sánchez-Hohl


IBCSG Coordinating Center
Effingerstrasse 40
CH-3008 Berne Switzerland
Phone: +41 31 511 94 24
Fax: +41 31389 92 29
Email: PALLAS-monitoring@ibcsg.org

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg52_pallas@fstrf.org

Date of Activation
March 31, 2016

Targeted Accrual
4600


News

23.03.2019:
The next IBCSG Annual Meeting will take place in Vienna Austria on March 23 and 24, 2019.       

09.09.2018:
9.9.2018 - RACE FOR LIFE, Bundesplatz Bern

28.06.2018:
Clinical Trials

All News

 
  Print